EP. 1: Clinical Pathways in Lung Cancer
Watch
EP. 2: Integrating New Lung Cancer Drugs Into a Formulary
EP. 3: Molecular Testing in NSCLC and Cost
EP. 4: Assessing Options in Second-Line NSCLC
EP. 5: Current Biomarkers in Lung Cancer
EP. 6: Cost-Benefit Analysis in Lung Cancer
EP. 7: Outcomes-Based Contracting in Lung Cancer
EP. 8: Frontline Decision Making in Nondriver Lung Cancer
EP. 9: Deciding on Second-Line Lung Cancer Therapy
EP. 10: Role of Immunotherapy in Lung Cancer
EP. 11: Rationale for Anti-Angiogenesis in Lung Cancer
EP. 12: Alternative Payment Models and Quality in Lung Cancer
EP. 13: The REVEL Study in Lung Cancer
EP. 14: Lung Cancer: Novel Combinations
EP. 15: Clinical Pathways in NSCLC
EP. 16: Communicating Policy Changes in Lung Cancer
EP. 17: Molecular Testing Coverage Decisions in Lung Cancer
EP. 18: Second-Line NSCLC Coverage Decisions
EP. 19: Considering Real-World Outcomes in NSCLC
EP. 20: Incentivizing Quality Care in NSCLC
EP. 21: Mutation Testing in Nonsquamous NSCLC
EP. 22: Nondriver NSCLC: Frontline Systemic Therapy
EP. 23: Maintenance Following Chemotherapy in NSCLC
EP. 24: NSCLC: Initiating Second-Line Therapy
EP. 25: Immunotherapy and Chemotherapy in Second-Line NSCLC
EP. 26: Nondriver NSCLC: Immunotherapy and PD-L1 Expression
EP. 27: Anti-Angiogenesis in NSCLC
EP. 28: Sequencing Therapies in NSCLC
